asenapine has been researched along with Psychotic Disorders in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Fujiwara, H; Murai, T; Takao, N | 1 |
| Morrissette, DA; Stahl, SM | 1 |
| Forcada, I; Grande, I; Hidalgo-Mazzei, D; Mur, M; Nieto, E; Sàez, C; Vieta, E | 1 |
| Raja, S | 1 |
| Novozhenova, TE; Oleichik, IV; Panteleeva, GP; Sokolov, AV | 1 |
| Castelnovo, A; Cavallotti, S; D'Agostino, A; Gambini, O; Guanella, E; Ostinelli, EG | 1 |
| Basra, MK; Byers, A; Dutta, S; Hay, A; Sereno, M | 1 |
| Fernández Monge, M; Lloreda Morillo, MJ; Robles Martínez, M | 1 |
| Baroni, S; Dell'Osso, L; Marazziti, D; Mucci, F; Mungai, F; Piccinni, A; Presta, S | 1 |
| Deshpande, S; Jones, PM; Orr, C; Sawh, S; Vasudev, K | 1 |
| Azar, MR; Geyer, MA; Gold, L; Marston, HM; Martin, FD; Meltzer, LT; Moore, CL; Serpa, KA; Shahid, M; Wong, EH; Young, JW | 1 |
| Emsley, R; Naber, D; Panagides, J; Schoemaker, J; Vrijland, P | 1 |
| de Greef, R; Dubovsky, SL; Frobose, C; Panagides, J; Phiri, P | 1 |
| Grant, JS; Keltner, NL; Moore, RL | 1 |
| Emsley, R; Naber, D; Panagides, J; Schoemaker, J; Stet, L; Vrijland, P | 1 |
| Dai, J; Huang, M; Li, Z; Meltzer, HY; Shahid, M; Wong, EH | 1 |
4 review(s) available for asenapine and Psychotic Disorders
| Article | Year |
|---|---|
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Dibenzocycloheptenes; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Impulsive Behavior; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Polypharmacy; Psychotic Disorders; Quetiapine Fumarate; Receptors, Dopamine D2; Risperidone; Thiazoles; Violence | 2014 |
Asenapine versus placebo for schizophrenia.
Topics: Adult; Antipsychotic Agents; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2015 |
Current Trends on Antipsychotics: Focus on Asenapine.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dibenzocycloheptenes; Half-Life; Heterocyclic Compounds, 4 or More Rings; Humans; Psychotic Disorders; Receptors, Adrenergic; Receptors, Serotonin | 2016 |
Asenapine for the Treatment of Psychotic Disorders.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Psychotic Disorders | 2017 |
3 trial(s) available for asenapine and Psychotic Disorders
| Article | Year |
|---|---|
Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Double-Blind Method; Heterocyclic Compounds, 4 or More Rings; Humans; Longitudinal Studies; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Treatment Outcome; Young Adult | 2010 |
Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Area Under Curve; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Psychotic Disorders; Schizophrenia | 2012 |
Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comparative Effectiveness Research; Diagnostic and Statistical Manual of Mental Disorders; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Longitudinal Studies; Male; Middle Aged; Olanzapine; Pharmacovigilance; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Time; Treatment Outcome; Weight Gain | 2012 |
9 other study(ies) available for asenapine and Psychotic Disorders
| Article | Year |
|---|---|
Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine.
Topics: Animals; Antipsychotic Agents; Dibenzocycloheptenes; Dopamine; Heterocyclic Compounds, 4 or More Rings; Humans; Psychotic Disorders; Retrospective Studies; Schizophrenia | 2021 |
Asenapine prescribing patterns in the treatment of manic in- and outpatients: Results from the MANACOR study.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depression; Dibenzocycloheptenes; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Outpatients; Personality Disorders; Prospective Studies; Psychotic Disorders; Retrospective Studies; Treatment Outcome | 2015 |
Neuroleptic malignant syndrome probably induced by asenapine.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Neuroleptic Malignant Syndrome; Psychotic Disorders; Young Adult | 2014 |
[Clinical experience and perspectives of using asenapine in stopping acute endogenous psychosis].
Topics: Acute Disease; Administration, Sublingual; Adult; Antipsychotic Agents; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heterocyclic Compounds, 4 or More Rings; Humans; Middle Aged; Patient Compliance; Psychometrics; Psychotic Disorders; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Asenapine in the Treatment of Acute Mania: A Real-World Observational Study With 6 Months Follow-Up.
Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Female; Follow-Up Studies; Heterocyclic Compounds, 4 or More Rings; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Patient Readmission; Psychiatric Status Rating Scales; Psychotic Disorders | 2015 |
Asenapine at low doses as a treatment for psychotic anxiety.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Dibenzocycloheptenes; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Psychiatric Status Rating Scales; Psychotic Disorders; Treatment Outcome; Young Adult | 2016 |
Asenapine effects in animal models of psychosis and cognitive function.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Attention; Benzodiazepines; Cognition; Dibenzocycloheptenes; Disease Models, Animal; Dose-Response Relationship, Drug; Heterocyclic Compounds, 4 or More Rings; Male; Olanzapine; Psychotic Disorders; Rats; Rats, Sprague-Dawley; Risperidone | 2009 |
Biological perspectives: update on newer antipsychotic drugs: are they evidence based?
Topics: Antipsychotic Agents; Cyclooxygenase 2 Inhibitors; Dibenzocycloheptenes; Evidence-Based Medicine; Heterocyclic Compounds, 4 or More Rings; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoindoles; Isoxazoles; Lactones; Lurasidone Hydrochloride; Piperidines; Psychotic Disorders; Pyridines; Serotonin Receptor Agonists; Sulfones; Thiazoles | 2011 |
Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Brain Chemistry; Dibenzocycloheptenes; Dopamine; Dose-Response Relationship, Drug; Extracellular Fluid; gamma-Aminobutyric Acid; Glutamic Acid; Heterocyclic Compounds, 4 or More Rings; Hippocampus; Male; Microdialysis; Norepinephrine; Piperazines; Prefrontal Cortex; Presynaptic Terminals; Psychotic Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Antagonists; Synaptic Transmission | 2008 |